Summit Therapeutics Inc. entered into a Collaboration and License Agreement with Akeso, Inc., issuing 10 million shares of common stock and paying $274.9 million in cash as an upfront payment.
AI Assistant
SUMMIT THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.